Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors

Edward Pan, Daohai Yu, Xiuhua Zhao, Anthony Neuger, Pamela Smith, Prakash Chinnaiyan, Hsiang Hsuan M.ichael Yu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A phase I study was conducted to evaluate the dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD)/recommended phase II dose of bendamustine with concurrent whole brain radiation (WBR) in patients with brain metastases (BM) from solid tumors. Four doses of intravenous weekly bendamustine were administered with 3 weeks of WBR at three dose levels (60, 80, and 100 mg/m(2)) according to a standard 3 + 3 phase I design. A total of 12 patients with solid tumor BM were enrolled in the study (six with non-small cell lung cancer, four with melanoma, one with breast cancer, and one with neuroendocrine carcinoma). The first two dose levels had three patients each, and the third dose level had six total patients. Plasma pharmacokinetic studies of bendamustine demonstrated no significant differences from pharmacokinetic characteristics of bendamustine in other studies. No DLTs were noted at any dose levels, and no grade 4 toxicities occurred. The MTD of weekly bendamustine with concurrent WBR was 100 mg/m(2). The majority of trial patients died from progressive systemic disease rather than their brain disease. The combination of weekly bendamustine with concurrent WBR was acceptably tolerated. The efficacy of this combination may be evaluated in a phase II trial with stratification by histologies.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalJournal of Neuro-Oncology
Volume119
Issue number2
DOIs
StatePublished - Sep 1 2014

Fingerprint

Radiotherapy
Neoplasm Metastasis
Brain
Radiation
Neoplasms
Maximum Tolerated Dose
Pharmacokinetics
Neuroendocrine Carcinoma
Brain Diseases
Non-Small Cell Lung Carcinoma
Brain Neoplasms
Bendamustine Hydrochloride
Melanoma
Histology
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. / Pan, Edward; Yu, Daohai; Zhao, Xiuhua; Neuger, Anthony; Smith, Pamela; Chinnaiyan, Prakash; Yu, Hsiang Hsuan M.ichael.

In: Journal of Neuro-Oncology, Vol. 119, No. 2, 01.09.2014, p. 413-420.

Research output: Contribution to journalArticle

Pan, Edward ; Yu, Daohai ; Zhao, Xiuhua ; Neuger, Anthony ; Smith, Pamela ; Chinnaiyan, Prakash ; Yu, Hsiang Hsuan M.ichael. / Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. In: Journal of Neuro-Oncology. 2014 ; Vol. 119, No. 2. pp. 413-420.
@article{3a69e1230a884226b239eedea785105d,
title = "Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors",
abstract = "A phase I study was conducted to evaluate the dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD)/recommended phase II dose of bendamustine with concurrent whole brain radiation (WBR) in patients with brain metastases (BM) from solid tumors. Four doses of intravenous weekly bendamustine were administered with 3 weeks of WBR at three dose levels (60, 80, and 100 mg/m(2)) according to a standard 3 + 3 phase I design. A total of 12 patients with solid tumor BM were enrolled in the study (six with non-small cell lung cancer, four with melanoma, one with breast cancer, and one with neuroendocrine carcinoma). The first two dose levels had three patients each, and the third dose level had six total patients. Plasma pharmacokinetic studies of bendamustine demonstrated no significant differences from pharmacokinetic characteristics of bendamustine in other studies. No DLTs were noted at any dose levels, and no grade 4 toxicities occurred. The MTD of weekly bendamustine with concurrent WBR was 100 mg/m(2). The majority of trial patients died from progressive systemic disease rather than their brain disease. The combination of weekly bendamustine with concurrent WBR was acceptably tolerated. The efficacy of this combination may be evaluated in a phase II trial with stratification by histologies.",
author = "Edward Pan and Daohai Yu and Xiuhua Zhao and Anthony Neuger and Pamela Smith and Prakash Chinnaiyan and Yu, {Hsiang Hsuan M.ichael}",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s11060-014-1510-6",
language = "English (US)",
volume = "119",
pages = "413--420",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors

AU - Pan, Edward

AU - Yu, Daohai

AU - Zhao, Xiuhua

AU - Neuger, Anthony

AU - Smith, Pamela

AU - Chinnaiyan, Prakash

AU - Yu, Hsiang Hsuan M.ichael

PY - 2014/9/1

Y1 - 2014/9/1

N2 - A phase I study was conducted to evaluate the dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD)/recommended phase II dose of bendamustine with concurrent whole brain radiation (WBR) in patients with brain metastases (BM) from solid tumors. Four doses of intravenous weekly bendamustine were administered with 3 weeks of WBR at three dose levels (60, 80, and 100 mg/m(2)) according to a standard 3 + 3 phase I design. A total of 12 patients with solid tumor BM were enrolled in the study (six with non-small cell lung cancer, four with melanoma, one with breast cancer, and one with neuroendocrine carcinoma). The first two dose levels had three patients each, and the third dose level had six total patients. Plasma pharmacokinetic studies of bendamustine demonstrated no significant differences from pharmacokinetic characteristics of bendamustine in other studies. No DLTs were noted at any dose levels, and no grade 4 toxicities occurred. The MTD of weekly bendamustine with concurrent WBR was 100 mg/m(2). The majority of trial patients died from progressive systemic disease rather than their brain disease. The combination of weekly bendamustine with concurrent WBR was acceptably tolerated. The efficacy of this combination may be evaluated in a phase II trial with stratification by histologies.

AB - A phase I study was conducted to evaluate the dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD)/recommended phase II dose of bendamustine with concurrent whole brain radiation (WBR) in patients with brain metastases (BM) from solid tumors. Four doses of intravenous weekly bendamustine were administered with 3 weeks of WBR at three dose levels (60, 80, and 100 mg/m(2)) according to a standard 3 + 3 phase I design. A total of 12 patients with solid tumor BM were enrolled in the study (six with non-small cell lung cancer, four with melanoma, one with breast cancer, and one with neuroendocrine carcinoma). The first two dose levels had three patients each, and the third dose level had six total patients. Plasma pharmacokinetic studies of bendamustine demonstrated no significant differences from pharmacokinetic characteristics of bendamustine in other studies. No DLTs were noted at any dose levels, and no grade 4 toxicities occurred. The MTD of weekly bendamustine with concurrent WBR was 100 mg/m(2). The majority of trial patients died from progressive systemic disease rather than their brain disease. The combination of weekly bendamustine with concurrent WBR was acceptably tolerated. The efficacy of this combination may be evaluated in a phase II trial with stratification by histologies.

UR - http://www.scopus.com/inward/record.url?scp=85028231962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028231962&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1510-6

DO - 10.1007/s11060-014-1510-6

M3 - Article

C2 - 24965340

AN - SCOPUS:85028231962

VL - 119

SP - 413

EP - 420

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -